Indoco Remedies Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Indoco Remedies Limited Pharmaceutical Export Portfolio Dataset — 13 Products, $73.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Indoco Remedies Limited — Pharmaceutical Exporter Profile (2026) | 13 Products, $73.5M Trade | TransData Nexus

Indoco Remedies Limited

Indian Pharmaceutical Exporter · Lipid & Metabolism Specialist · $73.5M Total Trade · DGFT Verified

Indoco Remedies Limited is an Indian pharmaceutical exporter with a total trade value of $73.5M across 13 products in 9 therapeutic categories. Based on 1,630 verified export shipments from Indian Customs (DGFT) records, Indoco Remedies Limited is the #1 Indian exporter in 1 product including Glimepiride. Top exports include Allopurinol ($34.1M), Paracetamol ($21.6M), Tramadol ($4.3M).

Indoco Remedies Limited — Export Portfolio & Destination Treemap

Indoco Remedies Limited pharmaceutical export portfolio — 13 products across 9 therapeutic categories. Source: Indian Customs (DGFT).

Who is Indoco Remedies Limited? — Company Overview & Market Position

Indoco Remedies Limited, established on August 23, 1947, is a fully integrated, research-oriented pharmaceutical company headquartered in Mumbai, India. The company specializes in the manufacturing and marketing of finished pharmaceutical formulations and active pharmaceutical ingredients (APIs). With a presence in 55 countries, Indoco has built a strong foothold in both domestic and international markets. As of the latest available data, Indoco reported a turnover of approximately US$ 180 million and employs around 6,000 personnel, including over 400 skilled scientists.

The company's manufacturing facilities adhere to the highest regulatory standards, complying with WHO-cGMP guidelines and holding approvals from various regulatory authorities such as the USFDA, UK-MHRA, TGA-Australia, SAHPRA-South Africa, and others. Indoco's diverse product portfolio spans therapeutic areas including gastrointestinal, anti-infectives, respiratory, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological segments.

What Does Indoco Remedies Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Allopurinol$34.1M

Product Portfolio — Top 13 by Export Value

Indoco Remedies Limited exports 13 pharmaceutical products across 9 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Allopurinol	Lipid & Metabolism	$34.1M	682	6.9%	3
2	Paracetamol	Analgesics & Antipyretics	$21.6M	432	6.0%	3
3	Tramadol	Analgesics & Antipyretics	$4.3M	87	1.1%	10
4	Albendazole	Antimalarial & Antiparasitic	$3.6M	167	5.0%	6
5	Montelukast	Respiratory	$3.0M	61	1.8%	9
6	Glimepiride	Diabetes & Endocrine	$2.0M	41	2.7%	1
7	Phenylephrine	Respiratory & OTC	$2.0M	66	2.4%	7
8	Febuxostat	Lipid & Metabolism	$976.4K	23	2.0%	8
9	Colchicine	Lipid & Metabolism	$733.8K	29	3.5%	8
10	Ras	Ayurvedic & Herbal Products	$400.0K	8	0.1%	15
11	Sulfasalazine	Gastrointestinal	$259.0K	11	8.1%	3
12	Moxifloxacin	Advanced Antibiotics	$239.8K	18	0.7%	14
13	Hydroxychloroquine	Antimalarial & Antiparasitic	$90.6K	5	0.1%	12

Indoco Remedies Limited exports 13 pharmaceutical products across 9 therapeutic categories with a total export value of $73.5M. The company is the #1 Indian exporter in 1 product: Glimepiride. The top category is Lipid & Metabolism (48.7% of portfolio), followed by Analgesics & Antipyretics (35.3%), indicating a concentrated portfolio with the top 5 products accounting for 90.8% of total export value.

Indoco Remedies Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Indoco Remedies operates multiple manufacturing facilities across India, each designed to meet specific production requirements and regulatory standards. The Goa Plant I, for instance, manufactures solid dosages, creams, ointments, and liquid dosages, with an annual capacity of 2 billion tablets, 6 million bottles of liquid orals, 10 million tubes of creams and ointments, and 60 million capsules. This facility holds approvals from the UK-MHRA, TGA-Australia, and WHO-GMP.

The Goa Plant II is a state-of-the-art sterile facility for ophthalmics and injectables, approved by the USFDA, Ministry of Health - Tanzania, UK-MHRA, ANVISA, ENVIMA, and NAFDAC-Nigeria. It has an annual capacity of 15 million ampoules and 20 million vials/bottles. Other facilities include the Baddi Plant I and II, which manufacture tablets, creams, ointments, liquid orals, and toothpaste, and the Waluj Plant, which produces solid orals, liquid orals, and external preparations. These plants are approved by various regulatory bodies, including the UK-MHRA, WHO-GMP, and others.

3Key Leadership

Indoco Remedies is led by a team of experienced professionals committed to the company's growth and strategic direction. Mr. Suresh G. Kare serves as the Non-Executive Chairman and Whole-time Director, bringing decades of experience to the role. Ms. Aditi Kare Panandikar holds the position of Managing Director and Executive Director, overseeing the company's operations and strategic initiatives. Mr. Sundeep V. Bambolkar serves as the Joint Managing Director and Executive Director, responsible for manufacturing, supply chain operations, finance, and international business.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Indoco Remedies Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Indoco Remedies has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. In the United States, the company has received final ANDA approvals from the USFDA for products such as Brivaracetam Oral Solution, Lacosamide Oral Solution, and Rivaroxaban Tablets, indicating a strong foothold in the generic pharmaceutical sector.

In the European Union, Indoco has secured EU GMP certification for its sterile drug product manufacturing facility at Goa Plant II, demonstrating compliance with European regulatory standards. The company's UK operations are approved by the UK-MHRA, ensuring adherence to stringent UK pharmaceutical regulations. In Australia, Indoco's Goa Plant I has been approved by the TGA, reflecting the company's commitment to meeting international quality standards.

2Emerging Markets

Indoco Remedies has strategically expanded its footprint in emerging markets across Africa, Latin America, and Southeast Asia. The company's manufacturing facilities have received approvals from regulatory authorities in countries such as Uganda, Tanzania, Kenya, and Zambia, facilitating access to these markets. Additionally, Indoco's commitment to quality is evident through its WHO-GMP certifications, which enhance its credibility and marketability in these regions.

Geographic Strategy

Indoco Remedies Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Indoco Remedies has demonstrated a strong commitment to meeting FDA standards, with multiple facilities registered with the USFDA. The company has received final ANDA approvals for products like Brivaracetam Oral Solution, Lacosamide Oral Solution, and Rivaroxaban Tablets, indicating successful regulatory submissions. The API manufacturing facility at Patalganga received an Establishment Inspection Report (EIR) from the USFDA, confirming compliance with FDA regulations. These approvals and inspections underscore Indoco's dedication to maintaining high-quality manufacturing practices.

2WHO & EU GMP

Indoco Remedies has achieved significant milestones in obtaining WHO-GMP and EU GMP certifications. The Goa Plant II has been certified by the European Health Authorities for compliance with EU GMP standards, reflecting the company's adherence to European pharmaceutical manufacturing practices. Additionally, the Goa Plant I holds WHO-GMP approval, demonstrating compliance with global quality standards. These certifications enhance Indoco's credibility and facilitate access to international markets.

3CDSCO & Indian Regulatory

Indoco Remedies Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Indoco Remedies operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. In the generic pharmaceutical sector, the company competes with firms such as Lupin Pharmaceuticals, Dr. Reddy's Laboratories, and Cipla, which have established global presences. Indoco differentiates itself by focusing on niche segments like ophthalmics and injectables, aiming to capture market share in these specialized areas. The company's adherence to international quality standards and regulatory approvals further strengthens its position in the market.

2Key Differentiators

Indoco Remedies distinguishes itself through its comprehensive product portfolio, which includes formulations across various therapeutic areas such as gastrointestinal, anti-infectives, respiratory, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological segments. The company's focus on niche segments like ophthalmics and injectables allows it to cater to specialized market needs. Additionally, Indoco's commitment to quality is evident through its WHO-GMP and EU GMP certifications, enhancing its credibility in international markets.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Indoco Remedies Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Indoco Remedies has established itself as

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Indoco Remedies Limited

How many pharmaceutical products does Indoco Remedies Limited export from India?

Indoco Remedies Limited exports 13 pharmaceutical products across 9 therapeutic categories. The top exports are Allopurinol ($34.1M), Paracetamol ($21.6M), Tramadol ($4.3M), Albendazole ($3.6M), Montelukast ($3.0M). Total export value is $73.5M.

What is Indoco Remedies Limited's total pharmaceutical export value?

Indoco Remedies Limited's total pharmaceutical export value is $73.5M, based on 1,630 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Indoco Remedies Limited the #1 Indian exporter?

Indoco Remedies Limited is the #1 Indian exporter in 1 products: Glimepiride (2.7% market share).

What therapeutic categories does Indoco Remedies Limited cover?

Indoco Remedies Limited exports across 9 therapeutic categories. The largest are Lipid & Metabolism (48.7%, 3 products), Analgesics & Antipyretics (35.3%, 2 products), Antimalarial & Antiparasitic (5.0%, 2 products).

Get Full Indoco Remedies Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.